Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications

By Taylor Carmichael - Jul 24, 2020 at 12:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.

Arbutus Biopharma ( ABUS -3.71% ) has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. Back in January 2019, Moderna ( MRNA 1.74% ), whose entire drug platform is based upon messenger RNA, filed a petition with the U.S. Patent Office to have the small biotech firm's drug-delivery patent declared invalid. Instead, on Thursday, the agency's Patent Trial and Appeal Board ruled in favor of Arbutus.

The ruling is important as Moderna's COVID-19 vaccine candidate uses technology that's covered by this patent. The experimental vaccines that the company is developing use mRNA to issue instructions to the body's cells to start manufacturing proteins that will trigger an immune system response. But a major issue with this method is the matter of treatment delivery -- how to get these instructions into the body's cells. Several years ago, Moderna licensed its delivery technology -- the use of lipid nanoparticles -- from a small Canadian company called Acuitas. That company, it turns out, had licensed its technology from Arbutus Biopharma -- and it did not have rights to sublicense it.

nanoparticle drug delivery mock-up

Image source: Getty Images

With the upholding of the Arbutus patent, it appears that Moderna might have to pay the smaller company some royalties. While Arbutus has yet to sue for those royalties, Moderna's attempt to invalidate the patent was an implicit admission that it was aware that the patent might cover its delivery system. In 2017, then-CEO of Arbutus Mark Murray said, "We have seen no evidence of a Moderna delivery system that is free of our intellectual property. Not in their publications, their presentations, or in the examples in their patent filings. In our view what they are reporting as theirs appears to be dominated by our intellectual property."

After the ruling, Arbutus' stock shot dramatically higher -- as of 12:50 p.m. on Friday, it was up by about 102% from its Wednesday closing price. Meanwhile, Moderna's stock has dropped by 10%, shaving a few billion off its market cap.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arbutus Biopharma Corporation Stock Quote
Arbutus Biopharma Corporation
ABUS
$4.15 (-3.71%) $0.16
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$306.72 (1.74%) $5.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.